The Chemours Company (NYSE:CC - Get Free Report) announced a quarterly dividend on Tuesday, May 5th. Shareholders of record on Sunday, May 17th will be paid a dividend of 0.0875 per share by the specialty chemicals company on Tuesday, June 16th. This represents a c) dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend is Friday, May 15th.
Chemours has decreased its dividend payment by an average of 0.1%annually over the last three years. Chemours has a dividend payout ratio of 14.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Chemours to earn $2.28 per share next year, which means the company should continue to be able to cover its $0.35 annual dividend with an expected future payout ratio of 15.4%.
Chemours Stock Performance
CC stock traded down $4.22 during midday trading on Wednesday, reaching $23.72. 4,277,307 shares of the company's stock traded hands, compared to its average volume of 3,325,129. The company has a 50-day moving average price of $20.96 and a two-hundred day moving average price of $16.48. The company has a debt-to-equity ratio of 16.33, a quick ratio of 0.85 and a current ratio of 1.78. Chemours has a 52 week low of $9.13 and a 52 week high of $28.67. The firm has a market capitalization of $3.56 billion, a PE ratio of -9.53 and a beta of 1.47.
Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.10. The business had revenue of $1.38 billion for the quarter, compared to analysts' expectations of $1.40 billion. Chemours had a negative net margin of 6.41% and a positive return on equity of 41.75%. The business's revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.13 EPS. As a group, equities analysts anticipate that Chemours will post 1.35 EPS for the current year.
Hedge Funds Weigh In On Chemours
Institutional investors and hedge funds have recently made changes to their positions in the business. Atlas Capital Advisors Inc. bought a new position in shares of Chemours during the fourth quarter valued at approximately $26,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Chemours during the fourth quarter valued at approximately $28,000. Covestor Ltd increased its position in shares of Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company's stock valued at $31,000 after acquiring an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Chemours during the fourth quarter valued at approximately $31,000. Finally, Rothschild Investment LLC increased its position in shares of Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company's stock valued at $32,000 after acquiring an additional 1,255 shares in the last quarter. Institutional investors own 76.26% of the company's stock.
About Chemours
(
Get Free Report)
Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.
Chemours' principal business activities are organized into three core segments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
